Investigating basal tear fluid as a diagnostic biofluid in dementia disorders: a NULISA-based evaluation from a mixed memory clinic cohort

Introduction The diagnostic work-up for Alzheimer’s disease (AD) is in constant development, and with recent discoveries deeming blood-based biomarkers ready for the clinic​, the search for new complementary​ biofluids is gaining momentum. Basal tear fluid (BTF) may represent a viable alternative biofluid, offering an accessible​ pool of potential biomarkers. Previous studies demonstrated that phosphorylated tau (p-tau) isoforms, and other additional neurodegeneration markers (e.g., amyloid-β (Aβ​), neurofilament light (NfL), α-synuclein) are measurable in BTF. However, these findings were generated using different immunoassay platforms and across multiple centers, limiting comparability. In this study, we measured neurodegeneration biomarkers in BTF using the NULISAseq CNS panel, with the aim of assessing detectability and proteomic signatures across amyloid status and clinical diagnoses in a target population recruited in two independent tertiary care centers. Methods BTF was collected using Schirmer strips from patients undergoing diagnostic evaluation for cognitive impairment in tertiary care. Diagnostic assessment included clinical evaluations and CSF sampling to determine amyloid status. Protein abundancies in BTF were quantified using the NULISAseq CNS Disease Panel. Detectability of proteins was assessed per manufacturer guidelines and visually using quantile-quantile plots. Differential expression analysis, adjusted for age and sex, was performed for biomarker discovery. Predictive modeling was performed using a full and reduced random forest models with bootstrap validation. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). Results In total, 108/122 targets present in the panel passed QC metrics and were included in analyses. Among these there were known neurodegeneration markers, such as NfL, glial fibrillary acidic protein, Aβ42, three brain-derived p-tau (BD-p-tau) isoforms and three p-tau isoforms. 11 proteins were associated with a clinical diagnosis of AD (Top 3: IL17A: log FC =-0.37, p unadj = 0.01; IGF1R: log FC =-0.14, p unadj =0.014, total BD-p-tau: log FC =-0.39, p unadj =0.016). However, significance was not retainable after correction for multiple testing. Random forest models demonstrated limited discriminative performance, with mean bootstrap AUCs ranging from 0.51 to 0.61. Conclusions Our findings demonstrate that neurodegeneration biomarkers are quantifiable in BTF, however with negligible differences across amyloid-positive and -negative individuals. Nevertheless, these findings warrant further investigation for BTF as a novel and easily accessible biomarker source in a memory clinic setting.

Authors

Institutions

Publication Details

Journal
Alzheimer s Research & Therapy
Published
2026-11-20
DOI
https://doi.org/10.1186/s13195-026-02265-4
Primary Topic
Dementia and Cognitive Impairment Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Investigating basal tear fluid as a diagnostic biofluid in dementia disorders: a NULISA-based evaluation from a mixed memory clinic cohort

Henrik Zetterberg, Guglielmo Di Molfetta, Nicholas James Ashton, Frederikke Kragh Clemmensen et al.
4 links
Alzheimer s Research & Therapy
Dementia and Cognitive Impairment Research
article

Investigating basal tear fluid as a diagnostic biofluid in dementia disorders: a NULISA-based evaluation from a mixed memory clinic cohort

Henrik Zetterberg, Guglielmo Di Molfetta, Nicholas James Ashton, Frederikke Kragh Clemmensen, Andréa Lessa Benedet, Anja Hviid Simonsen, Anna Dittrich, Silke Kern, Ingmar Skoog, Hannah H. Dabelsteen Wandall, Steen Gregers Hasselbalch
article en

Abstract

Introduction The diagnostic work-up for Alzheimer’s disease (AD) is in constant development, and with recent discoveries deeming blood-based biomarkers ready for the clinic​, the search for new complementary​ biofluids is gaining momentum. Basal tear fluid (BTF) may represent a viable alternative biofluid, offering an accessible​ pool of potential biomarkers. Previous studies demonstrated that phosphorylated tau (p-tau) isoforms, and other additional neurodegeneration markers (e.g., amyloid-β (Aβ​), neurofilament light (NfL), α-synuclein) are measurable in BTF. However, these findings were generated using different immunoassay platforms and across multiple centers, limiting comparability. In this study, we measured neurodegeneration biomarkers in BTF using the NULISAseq CNS panel, with the aim of assessing detectability and proteomic signatures across amyloid status and clinical diagnoses in a target population recruited in two independent tertiary care centers. Methods BTF was collected using Schirmer strips from patients undergoing diagnostic evaluation for cognitive impairment in tertiary care. Diagnostic assessment included clinical evaluations and CSF sampling to determine amyloid status. Protein abundancies in BTF were quantified using the NULISAseq CNS Disease Panel. Detectability of proteins was assessed per manufacturer guidelines and visually using quantile-quantile plots. Differential expression analysis, adjusted for age and sex, was performed for biomarker discovery. Predictive modeling was performed using a full and reduced random forest models with bootstrap validation. Model performance was evaluated using the area under the receiver operating characteristic curve (AUC). Results In total, 108/122 targets present in the panel passed QC metrics and were included in analyses. Among these there were known neurodegeneration markers, such as NfL, glial fibrillary acidic protein, Aβ42, three brain-derived p-tau (BD-p-tau) isoforms and three p-tau isoforms. 11 proteins were associated with a clinical diagnosis of AD (Top 3: IL17A: log FC =-0.37, p unadj = 0.01; IGF1R: log FC =-0.14, p unadj =0.014, total BD-p-tau: log FC =-0.39, p unadj =0.016). However, significance was not retainable after correction for multiple testing. Random forest models demonstrated limited discriminative performance, with mean bootstrap AUCs ranging from 0.51 to 0.61. Conclusions Our findings demonstrate that neurodegeneration biomarkers are quantifiable in BTF, however with negligible differences across amyloid-positive and -negative individuals. Nevertheless, these findings warrant further investigation for BTF as a novel and easily accessible biomarker source in a memory clinic setting.

Alzheimer s Research & Therapy
University of Copenhagen (DK), University of Arizona (US), Queen Mary University of London (GB), Sahlgrenska University Hospital (SE), Copenhagen University Hospital (DK), Rigshospitalet (DK), Region Västra Götaland (SE), Banner Sun Health Research Institute (US), Banner Alzheimer’s Institute (US), University of Gothenburg (SE)
Good health and well-being
Dementia and Cognitive Impairment Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon